I n v a
© Frank van Delft / Galapagos
o
© Frank van Delft / Galapagos
n t
Do you have any examples of partnerships with the pharmaceutical industry, biotech companies, foundations or universities in the fields of inflammation, osteoarthritis and fibrosis? Galapagos has had several collaborations with pharmaceutical companies in the past, and still has collaborations running with a number of them. Examples include GSK, Servier, Gilead and Abbvie. We have previously combined our own R&D activities with services for pharmaceutical companies. Recently, Galapagos concluded a transformative R&D agreement with American biopharma company Gilead. This means that for at least the next 10 years, Galapagos can continue to set its own course and continue to grow into an integrated international biotech company. In addition, it gives us access to sufficient financial strength to double our R&D organisation and support the further growth of the company. On top of this, we are continuously working with various academic centres to conduct basic research into diseases.
i o h n o l
For all other potential medicines in our pipeline, and for a period of 10 years, Gilead will have the option to inlicense after phase II. If Gilead opts in, Gilead and Galapagos will jointly conduct phase III research. For these programs, Galapagos will be responsible sales & marketing for Europe, and Gilead for the rest of the world, as soon as it receives the necessary approvals. If Gilead does not join, Galapagos may decide to take over the global marketing itself or to set up another partnership.
c
What are your prospects in terms of development? We remain focused on research into potential new medications. In doing so, we will substantially expand the basis for finding new targets. We hope to bring our first medication to patients next year. We also believe that many other medications will follow. We are not afraid to go down completely new roads in our research and development in order to make a genuine difference for patients. It is no coincidence that our motto is “Pioneering for patients. We discover. We dare. We care.”
T e
© Frank van Delft / Galapagos
n
Has Galapagos already established partnerships for the licensing and/or development of new medications? Yes, sure. For our first potential licensed medication, we have a partnership with American company Gilead. Once licensed, Galapagos aims to bring this medicine to patients in Belgium, the Netherlands and Luxembourg. For France, Spain, Germany, the United Kingdom and Italy, an agreement has been made with Gilead for shared market responsibility. Gilead is also responsible for marketing & sales outside Europe.
o g
In terms of therapeutic areas, where are you thinking of entering into future alliances? We are focused on our key areas, inflammation & fibrosis, in collaboration with our partner, Gilead. We also work on additional therapeutic areas, including osteoarthritis. Should Gilead decide not to opt in for any of our future programs, we can evaluate the possibility to close an alliance with other biotech or pharma partners, or alternatively, to bring these independently through clinical research and to patients. 61
y
Galapagos Generaal De Wittelaan L11 A3 - B-2800 Mechelen Tel.: +32 (0)15 34 29 00 - Fax: +32 (0)15 34 29 01 E-mail: communications@glpg.com http://www.glpg.com
